Background

Leigh Hochberg is the scientific director of the BrainGate consortium, a multi-institutional clinical research network in brain-computer interfaces. He holds faculty positions at Brown University and Massachusetts General Hospital, where he maintains active clinical research programs in neural prosthetics.

BrainGate Foundation

Hochberg was first author of the 2006 Nature paper from the BrainGate pilot trial, which reported neural-ensemble control of a computer cursor and prosthetic devices by a man with tetraplegia using an intracortical Utah array, and he leads the ongoing BrainGate2 clinical trial. This landmark publication established proof-of-concept for high-bandwidth BCIs and catalyzed subsequent commercial development by Neuralink, Blackrock, and other companies now pursuing similar methodologies.

Academic Leadership

As a professor at Brown University and senior lecturer at Harvard Medical School, Hochberg maintains influence over BCI research methodology, device design principles, and clinical trial conduct. The BrainGate consortium now spans Brown, Massachusetts General Hospital, VA Providence, Stanford, Emory, UC Davis and, since May 2026, Rice University and Baylor College of Medicine.

Continuing Innovation

Hochberg’s laboratory continues advancing speech neuroprosthetics, demonstrating real-time decoding of intended speech from paralyzed patients. In March 2026 a BrainGate team at Mass General Brigham including Hochberg reported typing at 22 words per minute with a 1.6% word error rate (Nature Neuroscience). His work bridges academic research and commercial development, establishing relationships with device manufacturers and regulatory agencies.

Research Philosophy

Hochberg emphasizes methodological rigor and long-term patient outcomes, contrasting with some commercial approaches focused on rapid advancement. His 20-year research trajectory demonstrates durability and safety considerations critical to clinical adoption.